Aquestive Therapeutics, Inc. (AQST)
After hours:
| Previous close | 3.4500 |
| Open | 3.5600 |
| Bid | 3.7800 x 400 |
| Ask | 3.8500 x 400 |
| Day's range | 3.5200 - 3.9150 |
| 52-week range | 1.2510 - 6.2300 |
| Volume | |
| Avg. volume | 1,686,609 |
| Market cap | 347.767M |
| Beta (5Y monthly) | 2.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4500 |
| Earnings date | 06 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.56 |
GlobeNewswireAquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs)Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pre-New Drug Application (NDA) meeting before the end of the third quarter WARREN, N.J., July 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company
GlobeNewswireAquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2024 and provide an update on recent developments in its business after market close on Tuesday, August 6, 2024. Management will host a conferen
ZacksNew Strong Sell Stocks for July 11th
AQST, CENTA and RAMP have been added to the Zacks Rank #5 (Strong Sell) List on July 11, 2024.
